Bupropion (Wellbutrin) is NOT inherently harmful for anxiety and can be safely used in most patients with anxiety, though SSRIs may have a modest advantage in severe anxious depression.
Evidence-Based Assessment
Bupropion does not worsen anxiety in most patients with depression and comorbid anxiety. The most robust evidence comes from a large naturalistic study (N=8,457) showing no difference in anxiety outcomes between bupropion and SSRIs over 12 weeks when using propensity-matched comparisons 1. Additionally, a meta-analysis of 10 randomized trials (N=2,890) found comparable anxiolytic efficacy between bupropion and SSRIs when treating anxiety symptoms in major depressive disorder 2.
When to Use Bupropion in Anxiety
First-line consideration:
- Patients with depression and mild-to-moderate anxiety symptoms 3, 4
- Depression with co-occurring anxiety where sexual dysfunction or weight gain from SSRIs is a concern 5
- Patients requiring smoking cessation alongside depression/anxiety treatment 6
The FDA label explicitly warns about monitoring for anxiety emergence 7, instructing clinicians to watch for "anxiety, agitation, panic attacks" especially early in treatment. However, this reflects general antidepressant warnings rather than bupropion-specific risk.
The Nuanced Reality: SSRIs vs Bupropion
For severe anxious depression (Hamilton anxiety-somatization factor ≥7), SSRIs show modest superiority. A pooled analysis of 10 studies (N=2,122) found SSRIs achieved 6% higher response rates than bupropion (65.4% vs 59.4%, p=0.03) in highly anxious patients 8. The number-needed-to-treat of 17 suggests this difference is statistically significant but clinically modest.
For moderate/low anxiety levels, there is no meaningful difference between bupropion and SSRIs 8, 2.
Practical Prescribing Algorithm
Start with lower doses and titrate gradually:
- Begin at 150 mg daily for 3 days, then increase to 150 mg twice daily if tolerated 9
- Monitor specifically for anxiety emergence in the first 12 weeks 10
- The second dose should be given before 3 PM to minimize insomnia risk 11
Use caution (but not avoidance) in:
- Patients with severe baseline anxiety—consider SSRIs first 10
- Higher doses (300 mg/day)—anxiety incidence increases dose-dependently with bupropion-containing combinations 10
Avoid in:
- Patients taking MAOIs (within 14 days) due to hypertensive crisis risk 10
- Seizure disorders or conditions lowering seizure threshold 9
Common Clinical Pitfalls
The myth of bupropion-induced anxiety is largely unfounded. While the FDA label warns about anxiety emergence 7, and clinical lore suggests bupropion is "activating," real-world evidence contradicts this concern 1. The 2023 naturalistic study definitively showed anxiety improved comparably with bupropion versus SSRIs when confounding variables were controlled.
Recent expert consensus (2026) explicitly recommends bupropion as first-line for MDD with co-occurring anxiety symptoms 5, representing an evolution in clinical thinking based on accumulating evidence.
Special Populations
In obesity with anxiety: The maximal dose of phentermine/topiramate ER (15 mg/92 mg) should be used cautiously, but standard-dose naltrexone-bupropion ER showed comparable anxiety rates to placebo (2.0% vs 1.6%) 10.
In smoking cessation: A large RCT found no increased neuropsychiatric adverse events with bupropion versus placebo in patients with or without psychiatric disorders 9.
Monitoring requirements per FDA label: Watch for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, and aggressiveness, particularly during initial treatment and dose adjustments 7. These symptoms warrant immediate clinical reassessment.